NCT01454479 2011-10-19A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or CarcinosarcomaChang Gung Memorial HospitalPhase 1 Unknown24 enrolled